Navigation Links
1st Pediatric Total Artificial Heart Patient Discharged Home Using Freedom® Portable Driver
Date:9/7/2011

TUCSON, Ariz., Sept. 7, 2011 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the SynCardia temporary Total Artificial Heart, announced today that Texas Children's Hospital in Houston has discharged its first pediatric Total Artificial Heart patient to wait for a matching donor heart at home. On Aug. 31, 18-year-old Jordan Merecka left the hospital using the Freedom® portable driver, a wearable power supply for his Total Artificial Heart.

(Photo: http://photos.prnewswire.com/prnh/20110907/LA63491)

"Having Jordan home again is the best gift in the world," said Suzanne Merecka, Jordan's mother. "The artificial heart was a blessing when he needed it desperately and his father and I are glad that Texas Children's could offer a life-saving option when things looked very grim. He still has a heart transplant in his future, but the artificial heart has helped him grow stronger. He will be ready when the time comes."

Jordan is participating in the FDA-approved Investigational Device Exemption (IDE) clinical study of the Freedom portable driver. Weighing 13.5 pounds, the Freedom driver is the first U.S. portable driver designed to power the Total Artificial Heart both inside and outside the hospital.  

"When I get home, I hope to be able to go fishing in the ponds in my neighborhood, hang out with my friends again, just relax, sit in my favorite chair," said Jordan. "I'm going to enroll in college classes while I'm waiting at home for my transplant."

Jordan was born with multiple congenital heart defects, including his heart on the wrong side of his chest (dextrocardia) and his heart vessels backwards (corrected transposition of the great arteries). In April 2011, Jordan was admitted to the hospital after he progressed to end-stage biventricular failure while awaiting a heart transplant. In May, all of his organs began to fail and he was placed on a ventilator. To save Jordan's life, on May 22, his doctors performed the hospital's first implant of SynCardia's Total Artificial Heart.

"It was always our plan to move Jordan to the Freedom driver as soon as he was strong enough and had met all the protocol guidelines," said Dr. David L.S. Morales, pediatric cardiovascular surgeon at Texas Children's Heart Center and associate professor of surgery and pediatrics at Baylor College of Medicine (BCM), who implanted the Total Artificial Heart. "Jordan will gain a morale boost by being out of the hospital, enjoying a more active teen life as he waits for heart transplantation."

Watch news stories about Jordan
View video of The Jordan Merecka Story: Parts 1 & 2 on YouTube
Read press release from Texas Children's Hospital

CAUTION – The Freedom® portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the Total is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. More than 950 implants account for more than 230 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end-stage biventricular failure. The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

In March 2011, Fast Company magazine ranked SynCardia #20 among the World's 50 Most Innovative Companies "for giving mobility to artificial heart recipients." Also in March, the longest running health and wellness series on public television, "Healthy Body, Healthy Mind," produced a 30-minute program featuring SynCardia's Total Artificial Heart. View here

For additional information, please visit: http://www.syncardia.com

Like SynCardia on Facebook

Follow SynCardia on Twitter – @SynCardia

Connect with SynCardia on LinkedIn

Media Contact:
Don Isaacs
Vice President of Communications
SynCardia Systems, Inc.
Cell: (520) 955-0660


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Texas Childrens Hospital is First Pediatric Hospital in the Nation to Implant Artificial Heart
4. Pediatrics Study Finds Children Taking ADHD Medications Did Not Suffer More Serious Heart Problems or Cardiovascular-related Death
5. New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis
6. Virginia Tech, Carilion team with physician to create digital ER pediatric response chart
7. European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
8. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
9. Cardon Children's Medical Center Adopts TrueVision 3D Surgical Visualization Platform for Department of Pediatric Neurosurgery
10. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
11. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed ... both viscous and elastic characteristics when deformed, which is identical to how the ... gently absorb compressive forces and return to its natural state along a hysteresis ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology:
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... -- CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog ... Used combined in one project, multi-biometric solutions provide ... ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
Breaking Biology News(10 mins):